Abbott Launches New Psoriasisanswers.com Web site

AbbottAugust marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information about what's happening to them can be a challenge. Abbott has launched Psoriasisanswers.com, a new educational Web site created to clear up the myths and provide facts and useful tools for people living with psoriasis.

Psoriasis is a chronic, immune disease that causes red, itchy, flaky and sometimes painful patches of skin anywhere on the body. While the exact cause is unknown, it's believed that at least 10 percent of the general population has a hereditary predisposition to the disease, though it develops in only 2-3 percent of people.

Psoriasisanswers.com offers useful tools and educational information for people living with the disease.

  • The Psoriasis Answers Widget delivers new tips and helpful facts about psoriasis every week to a personal desktop and has an interactive symptom tracker. This tracker allows patients or caregivers to privately compile detailed information about ongoing symptoms. When preparing for a visit with a dermatologist, tracker information can be printed and shared to enhance patient and doctor conversations.
  • The Psoriasis Answers Kit, which can be ordered on Psoriasisanswers.com, includes an offline version of the symptom tracker in the form of a notepad with stickers, plus Q&A Cards with tips, interesting facts and practical advice for people with the condition.

Beyond symptom tracking, Psoriasisanswers.com offers a guide to jumpstart disease discussions during office visits to ensure patients make the most of their face time with their dermatologist.

"I greatly support these types of online resources being available to psoriasis patients," says Dr. Bruce Strober, assistant professor in the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "It's very important to have information about the type and frequency of symptoms that is as accurate as possible. These tools help patients prepare for their appointments so they might have more productive and informative conversations with their physician."

Felicia Williams, who has psoriasis and is featured on Psoriasisanswers.com, urges people to be proactive about managing their condition. "It's important to take advantage of all the great resources out there like the tools on Psoriasisanswers.com. I'm thrilled to be able to share my story with others and encourage them to take control of their disease."

Psoriasis Awareness Month is sponsored by major patient advocacy organizations to encourage broader public awareness of the condition and support for people with it.

About Psoriasis
Psoriasis is a chronic, immune disease that appears on the skin. It affects an estimated 125 million people worldwide. It is a non-contagious disorder that speeds the growth cycle of skin cells and results in thick, scaly areas of skin. The most common form, called plaque psoriasis, appears as red, raised areas of skin covered with flaky white scales, which are often itchy and painful and can crack and bleed. Currently, there is no cure but treatment can help control the condition. Treatment may include topical agents, phototherapy or systemic medications taken orally or by injection or infusion. More information can be found at Psoriasisanswers.com.

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

FDA approves first treatment for rare form of skin…

The U.S. Food and Drug Administration has granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with m...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

TB Alliance sublicenses promising anti-tuberculosi…

On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug c...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]